AbbVie Inc (ABBV)vsTaseko Mines Ltd (TGB)
ABBV
AbbVie Inc
$207.18
+0.96%
HEALTHCARE · Cap: $362.83B
TGB
Taseko Mines Ltd
$6.20
+4.03%
BASIC MATERIALS · Cap: $2.26B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8989% more annual revenue ($61.16B vs $672.90M). ABBV leads profitability with a 6.9% profit margin vs -4.5%. TGB appears more attractively valued with a PEG of 0.33. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TGB
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1190.8%
Fair Value
$16.05
Current Price
$207.18
$191.13 premium
Intrinsic value data unavailable for TGB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Growing faster than its price suggests
Revenue surging 45.3% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
ROE of -4.7% — below average capital efficiency
Earnings declined 45.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : TGB
The strongest argument for TGB centers on PEG Ratio, Revenue Growth. Revenue growth of 45.3% demonstrates continued momentum. PEG of 0.33 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 87.0x leaves little room for execution misses.
Bear Case : TGB
The primary concerns for TGB are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.58 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while TGB is a hypergrowth play — different risk/reward profiles.
TGB carries more volatility with a beta of 1.89 — expect wider price swings.
TGB is growing revenue faster at 45.3% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 46/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Taseko Mines Ltd
BASIC MATERIALS · COPPER · USA
Taseko Mines Limited, a mining company, acquires, develops and operates mineral properties. The company is headquartered in Vancouver, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?